Track market-moving stories before they get noisy

SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all sellers of ChampionX Corporation (NASDAQ: CHX) common stock between February 29, 2024 and April 1, 2024. ChampionX is a global provider of chemistry solutions, artificial lift systems, and highly engineered equipment and technologies for the drilling and production of oil and gas.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What are the allegations?

Shareholders allege that ChampionX Corporation repurchased shares of its stock in violation of securities laws. According to the complaint, during the class period, defendants repurchased 216,000 shares of ChampionX stock – worth millions of dollars – from unsuspecting investors without disclosing material nonpublic information about Schlumberger Limited’s (SLB) offers to purchase ChampionX at a premium to then-current prices. If this information had been disclosed as required, it would have indicated to investors that ChampionX’s stock was worth significantly more than its trading price.

Plaintiff alleges that when investors learned the truth that SLB was willing to buy all the Company's outstanding stock for a significant premium above the trading price, ChampionX's stock price climbed sharply, harming investors who sold during the class period.

What can shareholders do now? You may be eligible to participate in the class action against ChampionX Corporation. Shareholders who wish to serve as lead plaintiff for the class must submit their papers with the court by July 14, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against ChampionX Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Commvault Systems, Inc. (NASDAQ: CVLT) securities between April 29, 2025 and January 26, 2026. Commvault is a data protection company.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What are the allegations?

Shareholders allege that Commvault Systems, Inc. misled investors regarding its annualized recurring revenue growth. According to the complaint, during the class period defendants created the false impression that Commvault’s annualized recurring revenue (ARR) growth would remain steady throughout fiscal year 2026. Plaintiff alleges that Commvault knew or recklessly disregarded that the Company’s ARR growth guidance failed to properly factor in crucial variables. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Commvault’s securities at artificially inflated prices.

Plaintiff alleges that the truth was revealed on January 27, 2026, when Commvault published third quarter 2026 fiscal results, which included ARR growth below the guidance provided by the Company. Commvault reported ARR growth for the third quarter 2026 was $39 million, which fell short of the $45 million projection provided. On this news, the price of Commvault’s common stock declined from a closing price of $129.36 per share on January 26, 2026, to $89.13 per share on January 27, 2026, a decline of over 31% in a single day.

What can shareholders do now? You may be eligible to participate in the class action against Commvault Systems, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers with the court by July 17, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Commvault Systems, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Editor’s note: This story has been updated to include a statement from Bloom Energy.

Bloom Energy told Benzinga that the company is aware of the report “published by a media outlet affiliated with an investment firm that has disclosed it may hold positions designed to profit from a decline in Bloom’s stock,” and plans to issue a response.

“We are reviewing the report and will correct the record. Bloom’s fuel cell platform is supported by a diversified, multi-country supply chain built over two decades, long-standing commercial relationships, and proprietary materials-recovery technology, as described in our public filings and our July 7 blog post on scandium oxide,” a Bloom Energy spokesperson said.

Executive Supply Chain Claims ContradictedThe decline follows findings by Hunterbrook challenging statements made by Bloom Energy CEO KR Sridhar regarding the company’s independence from Chinese materials.

Sridhar stated during an April 2025 earnings call, “We are not dependent on China for scandium,” adding, “there is no China supply chain for us.”

However, global trade data, corporate filings, and satellite imagery analyzed by the news outlet indicate that the fuel-cell manufacturer continues to rely on Chinese-sourced scandium, said Hunterbrook.

Hidden Routes And Supplier ConnectionsHunterbrook traced four separate China-linked routes delivering scandium into the manufacturer’s supply chain.

Deliveries involve direct shipments of scandium oxide from Hunan Oriental Scandium to a Delaware plant, as well as intermediaries routing materials through Thailand, Japan, and South Korea.

A sales representative from Hunan Oriental Scandium told reporters, “We are also BE’s largest supplier of scandium,” noting the material is “not exported directly.”

Widening Deficits And Delayed ProjectsHunterbrook’s supply-demand model indicates a looming global deficit for fuel-cell-grade scandium oxide.

The research shows Bloom Energy alone requires roughly 220 tons of scandium oxide to meet the 5 gigawatt production expectations modeled by Wall Street, while the total projected global supply reaches approximately 240 tons.

BE Stock Price Activity: Bloom Energy shares were down 9.89% at $242.91 at the time of publication on Wednesday, according to Benzinga Pro data.

Photo by Michael Vi via Shutterstock

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Key Takeaways Healthcare robotics is expanding into surgery, diagnostics, lab automation and orthopedics. Robotics ETFs are adding more healthcare automation exposure alongside industrial robotics. ETFs like ROBO offer exposure to healthcare automation innovators alongside robotics and AI companies. While electric vehicles and tech giants like Tesla (TSLA - Free Report) and Alphabet (GOOGL - Free Report) dominate headlines in the robotics space, a powerful transformation has reached an inflection point in healthcare. Over the past decade, robotics in medicine has moved from early adoption to mainstream scale. 

This acceleration has been driven by an aging global population, a persistent shortage of skilled surgeons and clinical staff, and the increasing push for minimally invasive procedures that offer faster recovery times and better patient outcomes. What was once dominated by the use of robots in a handful of guided surgeries has now expanded into varied branches ranging from orthopedics and pharmacy automation to artificial intelligence (AI)-driven diagnostics.

For investors looking to capitalize on this clinical migration, the challenge lies in differentiation. While standard healthcare funds offer stable dividends, they often dilute the tech-driven upside of advanced engineering. 

Broad robotics exchange-traded funds (ETFs), which have historically prioritized factory automation, material handling, and semiconductor equipment suppliers, have expanded their allocation to med-tech innovators like Intuitive Surgical (ISRG - Free Report) in the recent past. 

Evaluating the true potential of these robotics ETFs requires a ground-up look at the dominant healthcare stocks leading the charge and the clinical market dynamics driving their bottom lines.

Pioneering Stocks in Healthcare RoboticsSeveral key healthcare stocks demonstrate the broad range of robotics applications across the medical field, a few of which are discussed below.

•    Intuitive Surgical: As the pioneer in robotic-assisted surgery, its da Vinci system is a household name, allowing for complex procedures through small incisions. The company continues to show strong performance for this product, with Da Vinci procedures having risen approximately 16% year over year in the first quarter of 2026. 

ISRG grew its da Vinci surgical system installed base to 11,395 systems as of March 31, 2026, reflecting an increase of 12%. The new da Vinci 5 platform is driving higher utilization, and its data-rich ecosystem is creating a long-term competitive advantage in AI.

•    Illumina (ILMN - Free Report) : While best known for its gene-sequencing technology, Illumina is a prime example of robotics in lab automation. The company developed robotic systems like the Infinium Automated Pipetting System, which automates highly labor-intensive sample preparation workflows, as well as Digital Microfluidics, which is a droplet-based automation technology that moves, merges, and mixes liquid droplets using electrical signals. This minimizes human error and dramatically reduces processing time, which are critical for large-scale genomic studies and clinical diagnostics.

•    Stryker (SYK - Free Report) : A major player in medical devices, Stryker is a leader in orthopedic robotics. Its Mako system is used for robotic-arm assisted total knee, partial knee, and total hip replacements, offering surgeons enhanced precision and control. This technology has benefited the company's financial performance.

From surgical precision to laboratory efficiency, these examples illustrate how robotics is becoming integral to modern healthcare delivery across multiple specialties.

Industry Outlook and the Role of ETFsAs technology advances, we are moving closer to AI-enhanced surgical systems that improve decision-making, micro-robotic devices capable of navigating the human body for targeted therapy, and autonomous diagnostic tools that assist in early disease detection.

Against this backdrop, the outlook for healthcare robotics is exceptionally bright. According to a report published by Johns Hopkins University in May 2025, the global healthcare robotics market is expected to increase from approximately $14.9 billion in 2023 to $57.0 billion by 2032. 

While picking a single winner in this rapidly growing $57 billion market can be challenging, investing in a specialized robotics ETF provides a more balanced entry point. Rather than relying on a single clinical breakthrough, these funds grant investors exposure to the entire robotics value chain. 

This diversified approach can potentially boost profits by capturing growth across industrial automation, logistics, and other sectors, while mitigating the risk associated with any single company or sub-sector.

Robotics ETFs to ConsiderFor investors looking to tap into the robotics industry’s pioneering growth prospects, the following ETFs stand out: 

Global X Robotics & Artificial Intelligence ETF (BOTZ - Free Report)  

This fund, with net assets worth $3.43 billion, offers exposure to 62 companies that potentially stand to benefit from increased adoption and utilization of robotics and AI, including those involved in industrial robotics and automation, non-industrial robots, and autonomous vehicles. Keyence Corp holds the first spot in this fund, with 9.69% weightage, while ISRG holds the fifth position with 6.72% weightage. 

BOTZ has rallied 13.1% over the past year. The fund charges 68 basis points (bps) as fees and traded at a good volume of 1.33 million shares in the last trading session. 

ROBO Global Robotics and Automation Index ETF (ROBO - Free Report)

This fund, with net assets worth $2.09 billion, offers exposure to 79 companies that are driving transformative innovations in robotics, automation, and artificial intelligence (RAAI), including companies that create technology to enable truly intelligent systems that can sense, process, and act, and companies that apply those technologies to deliver RAAI-enabled products, including robots, to businesses and consumers. Harmonic Drive Systems holds the first spot in this fund, with 1.92% weightage, while ISRG holds the fourth position with 1.77% weightage. ILMN holds the sixth spot in this fund, with 1.69% weightage. 

ROBO has surged 36.2% over the past year. The fund charges 95 bps as fees and traded at a volume of 0.29 million shares in the last trading session. 

First Trust NASDAQ Artificial Intelligence and Robotics ETF (ROBT - Free Report)

This fund, with net assets worth $728.2 million, offers exposure to 114 companies engaged in AI, robotics and automation. Palo Alto Networks holds the first spot in this fund, with 1.87% weightage, while ILMN holds the fourth position with 1.75% weightage. 

ROBT has risen 15% over the past year. The fund charges 65 bps as fees and traded at a volume of 0.03 million shares in the last trading session. 

HomeDividends AnalysisREITs AnalysisReal Estate Analysis

SummaryKimco Realty Corporation has a solid balance sheet — $19.58B in total assets, an investment-grade A-/A-/A3 credit rating, and an asset coverage ratio (Total Assets/Debt) of ~236%.Preferred stocks KIM.PR.L (~6.54% current yield) and KIM.PR.M (~6.6%) trade below par and carry investment-grade ratings (Baa1/BBB/BBB).KIM has a portfolio of 565 properties and 100 million sq ft of leasable area, with the largest share being occupied by the "Grocery and Beverages" and "Restaurants" sectors.This idea was discussed in more depth with members of my private investing community, Trade With Beta. Learn More » Getty Images

In today's article, we will look into Kimco Realty Corporation (KIM), its financial metrics and ratios from the last quarter, and its financial instruments. We will look to the opportunities that they provide to us, as at the current

15.81K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in KIM.PR.M over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

, /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Peabody Energy Corporation (NYSE: BTU) common stock between October 14, 2024 and May 4, 2026, inclusive (the "Class Period"), have until August 24, 2026 to seek appointment as lead plaintiff of the Peabody Energy class action lawsuit. Captioned McGeachy v. Peabody Energy Corporation, No. 26-cv-01020 (E.D. Mo.), the Peabody Energy class action lawsuit charges Peabody Energy as well as certain of Peabody Energy's top current and former executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Peabody Energy class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-peabody-energy-corporation-class-action-lawsuit-btu.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

CASE ALLEGATIONS: Peabody Energy engages in the production of metallurgical and thermal coal.

The Peabody Energy class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Peabody Energy's Centurion mine ramp-up and anticipated growth; and (ii) there was a multitude of issues causing delays to the Centurion mine ramp-up and the return to full longwall production dates.

On March 30, 2026, Peabody Energy issued a press release allegedly lowering guidance pertaining to Centurion mine's expected first quarter 2026 output by 450,000 tons ahead of Peabody Energy's full earnings release. On this news, the price of Peabody Energy stock fell nearly 10%, according to the complaint.

Then, on May 5, 2026, Peabody Energy issued a press release allegedly disclosing Peabody Energy's failure to ramp-up Centurion by the long-awaited March 2026 deadline and that Peabody Energy was cutting guidance related to full year met segment volumes to reflect the increased cost and substantial volume decrease. On this news, the price of Peabody Energy stock fell nearly 6%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Peabody Energy common stock during the Class Period to seek appointment as lead plaintiff in the Peabody Energy class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Peabody Energy class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Peabody Energy class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Peabody Energy class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Contact:
          Robbins Geller Rudman & Dowd LLP
          Ken Dolitsky
          Michael Albert
          655 W. Broadway, Suite 1900, San Diego, CA 92101
          800/851-7783
          [email protected]

SOURCE Robbins Geller Rudman & Dowd LLP

July 08, 2026 16:10 ET  | Source: Monster Beverage Corporation

CORONA, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Monster Beverage Corporation (NASDAQ: MNST) today announced that its Board of Directors has approved and declared a 2-for-1 split of its common stock that will be effected in the form of a 100% stock dividend. Each stockholder of record on July 24, 2026 will receive a dividend of one additional share of common stock for each then-held share, to be distributed after close of trading on August 10, 2026. The Company anticipates its common stock to begin trading at the split-adjusted price on August 11, 2026.

Monster Beverage Corporation
Based in Corona, California, Monster Beverage Corporation is a holding company and conducts no operating business except through its consolidated subsidiaries. The Company’s subsidiaries develop and market energy drinks, including Monster Energy® drinks, Monster Energy Ultra® energy drinks, Juice Monster® and Punch Monster® Energy + Juice energy drinks, Java Monster® and Monster Killer Brew® non-carbonated coffee + energy drinks, Rehab® Monster® non-carbonated energy drinks, Monster Energy® Nitro energy drinks, Reign Total Body Fuel® high performance energy drinks, Reign Storm® and Storm™ total wellness energy drinks, NOS® energy drinks, Full Throttle® energy drinks, Bang Energy® drinks, FLRT™ total wellness energy drinks, BPM® energy drinks, BU® energy drinks, Burn® energy drinks, Live+® energy drinks, Mother® energy drinks, Nalu® energy drinks, Play® and Power Play® (stylized) energy drinks, Relentless® energy drinks, Samurai® energy drinks, Ultra Energy® drinks, Predator® energy drinks and Fury® energy drinks. The Company’s subsidiaries also develop and market craft beers, flavored malt beverages and hard seltzers under a number of brands, including Jai Alai® IPA, Dale’s Pale Ale®, Dallas Blonde®, Wild Basin® hard seltzers, The Beast™, Beast® Tea, Blind Lemon® and Blinder Lemon™. For more information visit www.monsterbevcorp.com.

Caution Concerning Forward-Looking Statements

Certain statements made in this announcement may constitute “forward-looking statements” within the meaning of the U.S. federal securities laws, as amended, regarding the expectations of management with respect to our future operating results and other future events including revenues and profitability. The Company cautions that these statements are based on management’s current knowledge and expectations and are subject to certain risks and uncertainties, many of which are outside of the control of the Company, that could cause actual results and events to differ materially from the statements made herein. Such risks and uncertainties include, but are not limited to, the following: the timing and completion of the stock split; our ability to sustain and/or surpass the current level of sales of our products, to adapt to changing consumer preferences, and to effectively respond to competitive products and pricing pressures; our ability to implement our growth strategy, including expanding our business in existing and new sectors and achieving profitability within our Alcohol Brands segment; our ability to adapt to the changing retail landscape with the rapid growth in e-commerce retailers and e-commerce websites; our ability to absorb, reduce or pass on to our bottlers/distributors increases in costs and expenses, including, but not limited to, increases to the cost of aluminum and other raw materials, the Midwest Premium, and freight costs; the impact of the current U.S. presidential administration’s policies on our energy drinks due to concerns about sugar-sweetened beverages, particular ingredients, such as food dyes, and the “generally recognized as safe” (GRAS) process; the impact of proposed or adopted domestic and/or foreign legislation to limit or restrict the sale of energy drinks (including the prohibition of the sale of energy drinks to certain demographics, at certain establishments, in certain container sizes or pursuant to certain governmental programs, such as the Supplemental Nutrition Assistance Program (SNAP)); the impact of changes in U.S. trade policies, including the imposition of additional tariffs; the impact of adverse changes in our costs, our supply chain, inflation or consumer demand for our products; the imposition of new and/or increased excise sales and/or other taxes on our products; our extensive commercial arrangements with The Coca-Cola Company (TCCC) and, as a result, our future performance’s substantial dependence on the success of our relationship with TCCC; the effects of unilateral decisions by bottlers/distributors and/or retailers on our business, including their distribution and placement of our products, their consolidation, their discontinuation, or restriction of the range of, all or any of our products that they carry, their limitations on the sale or sizes of our products, and/or their allocation of less resources to the sale of our products; changes in the price and/or availability of raw materials and other supply chain issues, such as the availability of products, suitable production facilities and/or co-packing arrangements; possible recalls of our products and/or the consequences and costs of defective production; disruption to our manufacturing facilities and operations related to climate, labor, production difficulties, capacity limitations, regulations or other causes; disruption to and/or lack of effectiveness of our information technology systems, including internal and external cybersecurity threats and breaches; adverse publicity surrounding obesity, alcohol consumption and other health concerns related to our products, product safety and quality; liabilities resulting from legal or regulatory proceedings, government investigations, and/or injunctions; the inherent operational risks, including the abuse or misuse of our products presented by the alcoholic beverage industry and/or related claims that may not be adequately covered by insurance or may lead to litigation; the current uncertainty and volatility in the national and global economy and changes in demand due to such economic conditions, including a slowdown in consumer spending generally; and the impact of military conflicts, including supply chain disruptions, volatility in commodity prices, increased economic uncertainty and escalating geopolitical tensions. For a more detailed discussion of these and other risks that could affect our operating results, see the Company’s reports filed with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2025 and our subsequently filed quarterly report. The Company’s actual results could differ materially from those contained in the forward-looking statements. The Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:Mark Astrachan SVP, Investor Relations & Corporate Development (951) 739-6200   Roger S. Pondel / Judy Lin PondelWilkinson Inc. (310) 279-5980

, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. ("GE HealthCare" or the "Company") (NASDAQ: GEHC) investors concerning the Company's possible violations of the federal securities laws.  

IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.

During the associated earnings call, management disclosed "profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier" and that "[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue."

On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%,  to close at $59.49 per share on April 29, 2026.

Contact Us To Participate or Learn More: 
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100, 
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice
Persons with non-public information regarding GE HealthCare should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About Glancy Prongay Wolke & Rotter LLP
GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm's recent successes, GPWR was named one of Law360's Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

SOURCE Glancy Prongay Wolke & Rotter LLP

Key Takeaways GKOS rallied after positive iDose TR commentary eased concerns over proposed Medicare coverage restrictions.GKOS reported $54M in first-quarter iDose TR sales and expects sequential growth in the second quarter.Glaukos is expanding with Epioxa adoption and a broad ophthalmology pipeline supporting long-term growth. Shares of Glaukos (GKOS - Free Report) have surged 45.7% since the end of May. The stock has outpaced the industry’s 4% gain and the S&P 500 Index’s 0.9% decline.

GKOS stock witnessed a sharp rally after the company announced better-than-expected first-quarter top and bottom-line figures on April 29. However, the stock pared all its gains in May amid uncertainty surrounding the proposed Local Coverage Determination (LCD) for its glaucoma therapy, iDose TR, by Medicare Administrative Contractors (MACs).

The MACs have proposed providing coverage for iDose only to patients who have failed both selective laser trabeculoplasty (SLT) and two topical medications. The proposal also restricts the concurrent use of iDose TR with minimally invasive glaucoma surgery (MIGS) procedures and limits re-administration of iDose TR to once every two years. These proposed restrictions could hurt the drug's commercial prospects.

However, Glaukos management seemed confident about receiving an exclusion or modification on some or all of these restrictions in the final LCD draft, while presenting at several investor conferences held during the end of May or early June. The company is focusing on promoting iDose TR as first-line treatment for ocular hypertension.

One-Month Performance

Image Source: Zacks Investment Research

GKOS management also stated that the market opportunity for iDose TR remains significant despite the proposed restrictions, driven by the rising number of glaucoma cases, and reaffirmed its guidance for 2026 and 2027. The company also believes that many patients are ineligible for SLTs or topical medications or both. GKOS is conducting a phase 4 study to evaluate the use of iDose TR with MIGS procedure, which has demonstrated promising results so far.

Several analysts also believe that the proposed restrictions for iDose TR in the proposed LCDs will have a minimal impact on its sales going forward. They expect a sizable pool of patients who have undergone selective laser trabeculoplasty (SLT) over the past decade to remain eligible for iDose TR.

The recent rally in Glaukos shares can be primarily attributed to investor enthusiasm following the positive commentary on iDose TR.  The company recorded $54 million in iDose TR sales during the first quarter of 2026. GKOS expects sales of the therapy to grow sequentially in the second quarter as well.

Other Factors Supporting the Rally

Rising Epioxa Adoption:Apart from iDose TR, Epioxa is emerging as Glaukos' next major growth engine, with management reporting an encouraging commercial launch despite being in its earliest phase. The company has rapidly built a treatment network covering nearly 65% of the U.S. population, with visibility to expand coverage to roughly 95%.

Reimbursement momentum is strengthening, supported by access pathways covering more than 100 million commercial lives. The drug is covered by four of the five largest U.S. payers and received a permanent J-code effective July 2026. Combined with direct-to-consumer awareness campaigns and physician education initiatives, these developments position Epioxa to meaningfully expand the underpenetrated keratoconus treatment market over time.

Strong Pipeline:Glaukos continues to differentiate itself through one of ophthalmology's broadest innovation pipelines, with 13 publicly disclosed programs spanning glaucoma, corneal disorders, retinal diseases and ocular surface therapies. Beyond commercial products like iDose TR and Epioxa, the company is advancing iDose TREX, iStent infinite for earlier-stage glaucoma, and PRESERFLO MicroShunt, iLution for Demodex blepharitis.

The company plans to initiate studies on next-generation iLink technologies and a keratoconus screening device later this year. Management also highlighted promising early-stage retinal assets and multiple Phase 4 studies that could expand reimbursement, strengthen clinical evidence and create additional label-expansion opportunities, supporting sustainable long-term growth beyond its current revenue drivers.

Key Challenges

Despite strong execution, Glaukos faces several operational challenges that could moderate near-term growth. Apart from uncertainty surrounding iDose TR LCDs, Epioxa's launch remains constrained by reimbursement complexity until the permanent J-code becomes fully operational, resulting in temporary claims-processing delays and slower physician adoption.

The company also expects international glaucoma growth to decelerate due to increasing competitive product launches and fading foreign-exchange tailwinds. Furthermore, management plans to accelerate investments in commercial infrastructure, patient awareness and direct-to-consumer initiatives, which will keep operating expenses elevated and delay margin expansion.

In addition, successful commercialization depends on increasing keratoconus diagnosis rates and expanding physician adoption, requiring sustained investment in education, payer engagement and market development before Epioxa can fully realize its long-term billion-dollar revenue potential.

A Glance at GKOS’ Estimates

The Zacks Consensus Estimate for GKOS’ 2026 loss per share is pinned at 57 cents, implying a year-over-year improvement of 36.7%. The Zacks Consensus Estimate for 2027 earnings per share is pegged at 47 cents, implying growth of 181% year over year. In the past 60 days, the consensus mark for the company's earnings has remained stable.

Revenues for 2026 are projected to grow 23.7% to $627.6 million and another 26.6% to $794.3 million in 2027.

Image Source: Zacks Investment Research

GKOS’ Zacks Rank and Stocks to Consider

Currently, Glaukos has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .

Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of 52 cents, which surpassed the Zacks Consensus Estimate by 52.94%. Revenues of $139 million beat the Zacks Consensus Estimate by 6.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.

VCYT has an estimated earnings growth rate of 5.1% for 2026 compared with the industry’s 14% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 45.88%.

West Pharmaceutical, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.37%.

Intuitive Surgical, carrying a Zacks Rank of 2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.3% compared with the industry’s 12.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%

Key Takeaways Denali gained 59.4% YTD as Avlayah approval marked its shift to a commercial-stage company.DNLI will receive $195 million from selling its Rare Pediatric Disease Priority Review Voucher.DNLI regained full rights to DNL593 after Takeda ended the partnership for strategic reasons. Denali Therapeutics, Inc. (DNLI - Free Report) has put up a stupendous year-to-date performance. Shares of the company have surged 59.4% year to date compared with the industry’s growth of 5.9%. The stock has outperformed the sector and the S&P 500 Index during this time frame.

The rally is largely attributed to investor optimism surrounding FDA approval of its lead drug, Avlayah, for the treatment of Hunter syndrome, as well as other regulatory updates.

DNLI Outperforms Industry, Sector & S&P 500 Index
Image Source: Zacks Investment Research

While the approval serves as a major catalyst, a deeper assessment of the company's growth drivers and potential risks will be essential to determine whether current levels represent an attractive entry point.

Avlayah Approval Positions DNLI for Long-Term UpsideAvlayah is an enzyme replacement therapy indicated for pediatric patients with Hunter syndrome (MPS II), targeting neurological symptoms when initiated early.

Developed by Denali, Avlayah is enabled by its TransportVehicle platform, which facilitates delivery of biologics throughout the body, including the brain.

Approval was based on strong biomarker data, showing a 91% reduction in cerebrospinal fluid heparan sulfate levels, a key disease marker.

This accelerated approval is particularly noteworthy as it introduces the first new therapeutic option for this rare disorder in nearly two decades. The continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory study.

Denali’s ongoing global phase II/III COMPASS study is expected to provide confirmatory data and support regulatory filings for tividenofusp alfa-eknm worldwide, including in young adult patients with Hunter syndrome.

The approval came with a Rare Pediatric Disease Priority Review Voucher (“PRV”).

Last month, DNLI entered into a definitive agreement to sell its PRV, which is expected to generate gross proceeds of $195 million.

The added financial flexibility will help advance Denali’s broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases.

DNLI’s Other Pipeline CandidatesDenali's clinical-stage portfolio includes DNL126 for Sanfilippo syndrome type A (MPS IIIA), DNL593 for GRN-related frontotemporal dementia, DNL952 for Pompe disease and DNL628 for Alzheimer's disease.

Denali is also advancing several early-stage pipeline candidates, including DNL921 for Alzheimer's disease, DNL111 for Parkinson’s and Gaucher diseases, DNL622 for Hurler syndrome (MPS I), and DNL422 (OTV) for Parkinson’s disease.

Denali has also collaborated with other pharma and biotech giants like Sanofi (SNY - Free Report) , Biogen (BIIB - Free Report) and Takeda (TAK - Free Report) to develop other candidates.

In May 2026, Denali and partner Biogen announced disappointing top-line results from a mid-stage study evaluating BIIB122 (DNL151) in individuals with early-stage Parkinson’s disease. The study did not meet its primary or secondary endpoints.

Biogen and Denali have discontinued the development of BIIB122 in idiopathic Parkinson’s disease.

Nonetheless, Denali will continue to independently advance the phase IIa BEACON study evaluating the small-molecule inhibitor in patients carrying pathogenic LRRK2 variants.

Partner Sanofi is developing eclitasertib for moderate-to-severe ulcerative colitis.

In April 2026, Denali announced that partner Takeda decided to terminate their collaboration for DNL593 (PTV:PGRN) in frontotemporal dementia associated with GRN mutations (FTD-GRN).

The termination returns full rights to the program to Denali. According to DNLI, Takeda's decision was driven by strategic priorities rather than any efficacy or safety concerns.

However, Takeda’s exit may raise concerns. Even though the decision was not tied to safety or efficacy, the loss of a large pharma partner removes external validation and shared financial burden.

Denali’s Valuation and EstimatesGoing by the price/book ratio, DNLI’s shares currently trade at 4.51X, higher than its mean of 3.02X for the industry and the industry’s mean of 3.64X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 loss per share has narrowed to $2.77 from $2.90 over the past 60 days, while that for 2027 loss has narrowed to $2.53 from $2.69 in the same time frame.

Image Source: Zacks Investment Research

Invest in DNLI Stock NowThe approval of Avlayah represents Denali’s transition into a commercial-stage company and a potential inflection point in its long-term growth trajectory. As its first marketed product, Avlayah introduces a new revenue stream, though the pace and scale of commercialization will be critical in determining its ultimate financial impact.

Beyond near-term revenues, the approval also validates Denali’s proprietary TransportVehicle platform, which is designed to enable biologic therapies to cross the blood-brain barrier — an area that has historically posed significant challenges.

On the financial front, Denali appears well capitalized, ending the first quarter with approximately $1.05 billion in cash and investments. This provides sufficient runway to support ongoing clinical development and strategic initiatives. Narrowing loss estimates indicate improving investor sentiment and a clearer path toward operational leverage.

The sale of PRV provides a significant non-dilutive capital infusion, strengthening the company’s balance sheet without requiring an equity raise.

We remain bullish on the stock's prospects and believe it offers additional upside potential. Accordingly, we view the shares favorably for prospective investors, while existing shareholders may consider maintaining their positions to capitalize on further growth opportunities.

Key Takeaways VIAV lifted non-GAAP operating margin to 21% as NSE and OSP revenue posted strong year-over-year growth.VIAV expects operating margin to reach 22.7% in the fourth quarter, up from 21% in the third quarter.VIAV's earnings estimates for 2026 were unchanged, while 2027 estimates improved over the past 60 days. Viavi Solutions, Inc. (VIAV - Free Report) reported a non-GAAP operating income of $85.5 million, up from $47.7 million a year ago quarter. Non-GAAP operating margin was 21%, up from 16.7% a year ago.

The improvement in operating margin is driven by multiple factors, including strong growth in the Network and Service Enablement segment (NSE) and Optical Security and Performance Products (OSP). In the third quarter of fiscal 2026, the NSE segment generated $321.5 million in revenues, up 54.4% year over year. The segment accounted for 79% of total revenues. Acquisition of Spirent product lines and strong demand across lab, production and field products, mainly from the data center ecosystem and aerospace & defense sectors, drove solid sales growth in this segment. The OSP segment revenues were $85.3 million, up 11.4% year over year, driven by strong demand for 3D Sensing and anti-counterfeiting.

Higher revenue is allowing fixed costs to be spread across a larger sales base. This is resulting in a significant operating leverage. Every incremental dollar of NSE revenue contributes roughly 40-45 cents to operating income, reflecting a highly scalable cost structure. Increasing mix, AI infrastructure and data center business, backed by hyperscalers’ demand, investment by optical module vendors and semiconductor companies will likely drive operating margin in the coming quarters. In the fourth quarter, Viavi expects its operating margin to reach 22.7%, up from 21% in the third quarter.

Other Tech Firms With Strong Margin ExpansionSanmina Corporation (SANM - Free Report) reported a non-GAAP operating profit of $257 million in the second quarter of 2026, up from $111 million a year ago. Non-GAAP operating margin improved to 6.4% from 5.6%. The 131.5% increase year over year and an 80-basis point operating margin expansion are driven by a multitude of factors. The ZT system, which performed significantly better than expected, was one of the biggest contributors. Strong customer demand for accelerated compute systems and earlier-than-expected shipments supported Sanmina’s profitability. Sanmina’s revenues surged 102.3% year over year to $4.01 billion. Revenue growth significantly outpaced the increase in operating expenses. Disciplined cost management was also a key contributor in this regard.

HubSpot. Inc. (HUBS - Free Report) generated a non-GAAP operating income of $156.8 million, up from $100.3 million in the prior-year quarter, with margin expanding 380 basis points year over year to 17.8%. Higher revenues and operating discipline helped offset increased investments in research, AI innovation and sales initiatives. HubSpot continues to witness rising adoption among larger customers as businesses consolidate marketing, sales and service workflows on a unified AI-enabled platform. During the first quarter of 2026, deals above $60,000 in annual recurring revenues increased 37% year over year, while deals above $120,000 ARR rose 64%. HubSpot’s AI strategy is increasingly contributing to customer engagement and monetization.

VIAV’s Price Performance, Valuation and EstimatesViavi has gained 290.8% in the past year compared with the Electronics - Measuring Instruments industry’s growth of 287%.

Image Source: Zacks Investment Research

Going by the price/earnings ratio, the company’s shares currently trade at 32.8 forward earnings, lower than 41.94 for the industry and its mean of 37.66.

Image Source: Zacks Investment Research

The company’s earnings estimates for 2026 have remained unchanged and 2027 have improved over the past 60 days.

Image Source: Zacks Investment Research

VIAV carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The tribunal on Wednesday determined that Prime Medicine’s investigational gene-editing therapy PM647 falls within the scope of the companies’ 2019 Collaboration and License Agreement.

The decision clears the company of any breach of contract claims and eliminates any financial liability related to the case.

Tribunal Rules PM647 Falls Within Prime Medicine’s Licensed FieldAccording to Prime Medicine, the arbitration tribunal concluded that PM647 is covered under the company’s defined “Field” in the 2019 agreement with Beam Therapeutics.

As a result, the tribunal found that Prime Medicine did not violate the terms of the agreement.

The company added that the ruling also determined it owes no monetary damages to Beam Therapeutics, bringing the previously disclosed arbitration to a close.

PM647 Targets Most Common Cause of Alpha-1 Antitrypsin DeficiencyPM647 is Prime Medicine’s investigational Prime Editing therapy for Alpha-1 Antitrypsin Deficiency (AATD).

The therapy uses the company’s universal liver lipid nanoparticle (LNP) delivery platform to correct the E342K (Pi*Z) mutation in the SERPINA1 gene, which the company said is the most common disease-causing mutation associated with AATD.

Prime Medicine said that in fully humanized mouse models, PM647 achieved high editing efficiency while restoring the corrected M-AAT protein isoform to healthy human levels at clinically relevant doses.

Clinical Development Timeline Remains On TrackFollowing the arbitration outcome, Prime Medicine said it remains on schedule to advance PM647 into the clinic.

The company plans to submit an investigational new drug application and/or a clinical trial application for PM647 during the third quarter of 2026.

If those filings proceed as planned, Prime Medicine expects to report initial clinical data from the program in 2027.

PRME Price Action: Prime Medicine shares were up 13.16% at $4.51 at the time of publication on Wednesday, according to Benzinga Pro data.

Photo by Gorodenkoff via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

BridgeBio Pharma (BBIO - Free Report) is building its investment case around rare diseases where diagnosis, targeted treatment and commercial access are changing quickly.

Attruby's launch in transthyretin amyloid cardiomyopathy gives the company a commercial base, while late-stage programs could widen its reach in genetic diseases with limited approved options.

Attruby Shows BridgeBio Demand ExpansionAttruby is already BridgeBio's main revenue driver. The drug generated $362.4 million in U.S. sales in 2025, its first full year on the market, and nearly $181 million in first-quarter 2026 sales.

The demand backdrop matters as much as the product launch. BridgeBio estimates diagnosed ATTR-CM patients in the United States increased from fewer than 5,000 in 2019 to more than 50,000 in 2025 as awareness improved and non-invasive diagnostic tools gained wider use.

This makes Attruby part of a broader market-expansion story. A larger identified patient pool can support continued adoption if BridgeBio converts diagnosis growth into prescriptions and maintains access against entrenched alternatives.

BBIO Targets First-in-Class OpportunitiesBridgeBio's late-stage pipeline is aimed at rare diseases where established therapies remain limited. BBP-418 is under FDA review for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), with a decision expected by Nov. 27, 2026.

If approved, BBP-418 would become the first therapy for that patient group and potentially the first approved treatment for any form of limb-girdle muscular dystrophy. Encaleret offers a similar first-in-class angle in autosomal dominant hypocalcemia type 1 (ADH1), with a possible U.S. launch in early 2027.

The strategy fits BridgeBio's broader focus on genetically defined diseases. It also gives investors multiple regulatory catalysts beyond Attruby, although approval timing and label breadth remain key variables.

How Oral Drugs Shape BridgeBio's PositioningProduct format is part of BBIO's competitive pitch. Infigratinib is an orally administered therapy being developed for achondroplasia, with a U.S. filing planned for the third quarter of 2026.

That oral profile could matter in a market that already includes injectable options. BioMarin Pharmaceutical (BMRN - Free Report) markets Voxzogo in achondroplasia, while Ascendis Pharma (ASND - Free Report) adds another competitive reference point through Yuviwel.

Attruby also operates in a competitive field. Pfizer (PFE - Free Report) remains the established player in ATTR-CM through its Vyndaqel family, which means BridgeBio must compete on clinical relevance, access and physician adoption rather than diagnosis growth alone.

BridgeBio Builds Beyond a One-Product StoryBridgeBio is still highly dependent on Attruby, but its portfolio points beyond a single commercial win. The company is preparing for three potential U.S. launches over the next 12 months, supported by a $1 billion preferred equity financing.

Earlier-stage assets add a longer runway. BBP-812 is being developed for Canavan disease, while a next-generation ATTR-CM depleter program could extend BridgeBio's presence in the same cardiac amyloidosis market over time.

Minority interests in GondolaBio and BridgeBio Oncology Therapeutics add rare disease and oncology optionality. These assets are not central to the near-term thesis, but they reinforce the company's effort to build a broader genetic-disease platform.

How BBIO Signals Trend Strength to InvestorsThe bottom line is that BridgeBio gives investors credible exposure to rare disease diagnosis growth, targeted therapy development and underpenetrated patient populations. Attruby validates the commercial side, while BBP-418, encaleret and infigratinib could determine whether BBIO becomes a broader launch story.

BBIO currently carries a Zacks Rank #3 (Hold). That rank is consistent with a balanced view in which launch execution and market expansion are offset by competition, regulatory risk and valuation pressure. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

For now, the investment debate rests less on the attractiveness of rare disease trends and more on execution. Attruby must keep gaining share, and the pipeline needs approvals that can diversify revenues without adding avoidable launch risk.

The AI infrastructure boom is still in its early days. Alphabet (GOOG 2.04%) (GOOGL 1.89%) has initiated an $84.75 billion equity capital raise "to expand AI infrastructure and compute," while Amazon (AMZN 1.23%) more recently issued over $25 billion in corporate bonds for AI investments.

All that money has to go somewhere, and some of it can flow into Sterling Infrastructure's (STRL 2.03%) coffers. The construction company has turned into a top AI data center builder, and as demand for those facilities rises, Sterling Infrastructure will continue to build on its backlog.

Image source: Getty Images.

The e-infrastructure opportunity Sterling Infrastructure is a site development specialist for residential and commercial properties. It also helps with transportation infrastructure, which includes highways, roads, and bridges. Those parts of the business had moderate growth in the first quarter, but they were completely overshadowed by e-infrastructure.

Today's Change

(

-2.03

%) $

-13.68

Current Price

$

660.71

That's the part of the business that's focused on AI data centers, e-commerce warehouses, and advanced manufacturing facilities. Its revenue was up by 174% year over year in the quarter, and a $5.15 billion backlog offers clear revenue visibility for multiple years. Sterling Infrastructure was recently awarded a contract to develop a large, multi-year semiconductor fabrication campus. The company has secured the initial developmental phase of that project and could end up building the entire facility.

AI infrastructure demand won't be slowing down anytime soon. Alphabet and Amazon are going deep into their pockets and raising capital to build more sites and buy key components that enable AI technology. E-infrastructure has served as a major catalyst, and if its revenue continues to accelerate, overall sales will go up with it.

Assessing the 30% drop Although Sterling Infrastructure enjoys solid fundamentals and AI spending continues to climb, the stock is down by more than 30% from all-time highs. Furthermore, it's down by more than 20% over the past month. This isn't a Sterling Infrastructure problem, since many AI stocks have endured sharp corrections over the past month.

Even Micron (MU +0.93%) wasn't safe. More than quadrupling revenue year over year wasn't enough for the company to avoid a 20% downturn in less than two weeks.

The fact that many AI stocks and tech companies are in the middle of corrections indicates that Sterling Infrastructure is not suffering from company-specific issues. Its fundamentals are improving despite the sell-off, and investors will soon pick up on that opportunity.

Sterling Infrastructure's full-year revenue projections also point to meaningful expansion. It's expected to reach $3.75 billion in total revenue at the midpoint, which represents a 50.6% year-over-year growth rate from the $2.49 billion in total revenue in full-year 2025.

While some investors are cashing out, others can benefit by investing in the dip and capitalizing on long-term AI tailwinds at a discount.

Marc Guberti has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, Micron Technology, and Sterling Infrastructure. The Motley Fool has a disclosure policy.

Helen of Troy Limited (HELE) Q1 2027 Earnings Call Transcript

Domino's Pizza Inc (NYSE:DPZ) is expected to report weaker-than-expected US same-store sales for the second quarter as macroeconomic pressures, elevated promotional activity across the pizza category and tougher year-over-year comparisons weigh on performance, according to UBS.

Ahead of the company's July 20 earnings report, the brokerage wrote that investors are likely to focus on current and planned sales initiatives, as well as management's outlook for sales in the second half of the year.

UBS forecasts US same-store sales will decline 1.5% in the second quarter, compared with Wall Street consensus expectations for 0.3% growth. The analysts wrote that softer consumer spending and heightened promotional competition are likely to offset benefits from value offers, marketing investments, the company's loyalty program and third-party delivery partnerships.

The firm expects management to highlight initiatives aimed at improving sales momentum, including continued value promotions, further growth through DoorDash, enhancements to Domino's app and loyalty platform, increased marketing and new menu offerings.

UBS also expects the company to discuss product innovation, including new sauces, expanded chicken options and additional crust platforms following the launch of Parmesan Stuffed Crust. The analysts added that store closures among competitors could help Domino's expand its market share over time.

While UBS continues to view Domino's as well-positioned for longer-term market share gains and global expansion, it sees risks to the company's current 2026 guidance.

UBS wrote that it sees downside risk to the company's current 2026 guidance, including low-single-digit growth in US and international same-store sales and mid- to high-single-digit operating income growth, excluding foreign exchange effects and the benefit of a 53rd week.

Outside the US, UBS forecasts global net store growth of 4.6% in the second quarter, in line with consensus estimates, including 31 net new stores in the US and 165 internationally. The analysts noted that global expansion outside Domino's Pizza Enterprises remains a relative strength, supported by attractive franchise economics, strong franchisee profitability, competitor closures and contributions from key international markets.

UBS added that investors are also likely to focus on Domino's Pizza Enterprises, including the arrival of its new chief executive in August, management's confidence in its turnaround strategy and potential portfolio changes to improve performance.

The firm maintained its $375 price target, saying Domino's valuation appears near a support level despite ongoing macroeconomic uncertainty, with longer-term upside supported by the company's potential to gain market share and accelerate sales growth through its strategic initiatives.

Shares of Domino’s traded hands at $305 on Wednesday afternoon.

EUR/USD holds firm on Wednesday after reversing earlier losses triggered by renewed tensions between the United States (US) and Iran, while traders digest the June Federal Open Market Committee (FOMC) meeting minutes. At the time of writing, the pair is trading around 1.1427 after hitting an intraday low of 1.1391.

The US Dollar (USD) saw little immediate reaction to the minutes, suggesting much of the Federal Reserve's (Fed) message was already reflected in market pricing. The US Dollar Index (DXY), which tracks the Greenback's value against a basket of six major currencies, is trading around 100.97, easing from an intraday high of 101.27.

Officials remained cautious about inflation, which remains well above the central bank's 2% target, while describing labor market conditions as balanced.

Policymakers also signaled that the future path of interest rates will depend on incoming economic data, with some indicating that additional policy tightening could be warranted if inflation proves more persistent than expected.

Nevertheless, renewed geopolitical tensions and expectations that the Fed could deliver at least one interest rate hike this year should continue to underpin the Greenback, keeping downside pressure on EUR/USD.

Technical analysis:

On the daily chart, EUR/USD is trading within a downward parallel channel and beneath its key moving averages, which keeps the near-term bias bearish.

However, momentum is showing signs of improvement, with the Relative Strength Index (RSI) recovering to 41 from near-oversold territory, while the Moving Average Convergence Divergence (MACD) has turned marginally positive, reinforcing the idea of a consolidative phase within a broader downside structure rather than a clear bullish reversal.

On the topside, initial resistance is seen at the horizontal level around 1.1500, closely aligned with the upper boundary of the descending channel, forming a tight cap on any corrective bounce.

Above these, the 100-day Simple Moving Average (SMA) at 1.1611, followed by the 200-day SMA at 1.1649, represent more substantial barriers that would need to be reclaimed to ease the prevailing bearish tone.

On the downside, immediate support emerges at the horizontal level near 1.1350, ahead of the channel floor around 1.1305, where a break would likely open the way for a continuation of the broader downtrend.

(The technical analysis of this story was written with the help of an AI tool. Know more.)

CALGARY, Alberta, July 08, 2026 (GLOBE NEWSWIRE) -- Brookfield Residential Properties ULC (“Brookfield Residential” or the “Company”) today announced that its 2026 second quarter results will be released after market closes on Wednesday, July 29, 2026. The financial results and information relating to the 2026 second quarter will be posted on the Company’s website at BrookfieldResidential.com.

Current holders and beneficial owners of, and prospective investors in, Brookfield Residential’s debt securities, securities analysts, market makers and other interested parties are invited to participate in the conference call on Thursday, July 30, 2026 at 11:00 am (EST) to discuss the Company’s results of operations during the second quarter of 2026 and current business initiatives with members of senior management. To participate in the live conference call from North America, dial 1.833.821.3184 and if you reside outside of North America, dial 1.647.846.2582. Telephone replay of the conference call will be available for one month following the scheduled call, until end of day August 30, 2026. To listen to the telephone replay from the United States or Canada, dial 1.855.669.9658, and if you reside outside of the United States or Canada dial 1.412.317.0088. Once prompted enter the replay access code, 8343650.

Brookfield Residential Properties ULC is a leading land developer and homebuilder in North America.  We entitle and develop land to create master-planned communities, build and sell lots to third-party builders, and conduct our own homebuilding operations. We also participate in select, strategic real estate opportunities, including infill projects, mixed-use developments, and joint ventures. We are the flagship North American residential property company of Brookfield Corporation (NYSE: BN; TSX: BN), a global alternative asset manager. Further information is available at BrookfieldResidential.com or Brookfield.com or contact:

Investor Relations
Tel: 855.234.8362
Email: [email protected]

D-Wave Quantum Inc (NYSE:QBTS) was last seen off 2.7% to trade at $20.50, poised to nab its fifth loss in the past five sessions and trading at its lowest levels in over a month. However, a historically bullish signal now flashing points to a potential rebound.

According to Schaeffer's Senior Quantitative Analyst Rocky White, QBTS is trading within 0.75 times the 100-day moving average's 20-day average true range (ATR), after spending at least 80% of the previous two weeks and 80% of the prior 42 trading sessions above that trendline.

This setup has appeared five times over the last decade, after which the stock was higher one month later 60% of the time, averaging an impressive 28% gain. A similar move from the stock's current perch would have it trading at $26.24.

Short interest remains elevated with the 55.75 million shares sold short now accounting for 15.54% of QBTS' available float, and it would take short sellers roughly two days to buy back their bearish bets at the stock's average pace of trading.

It's also worth noting the equity's Schaeffer's Volatility Index (SVI) of 98% stands higher than just 20% of all other readings from the past year, implying that near-term option traders are pricing in relatively low volatility expectations.

SpaceX moved Bitcoin (BTC) on-chain for the first time in six months on Tuesday. The company sent an $88 test transaction between two of its tagged wallets, blockchain tracker Arkham Intelligence reported.

The tiny transfer instantly revived a familiar question. SpaceX holds 18,712 BTC, and Elon Musk’s companies rarely touch their coins without drawing market attention.

Is SpaceX Moving Its Bitcoin?Arkham flagged the transaction on Wednesday. The funds traveled from a legacy “15atF” address to a newer “bc1q9” address.

SpaceX Bitcoin test transaction between tagged wallets. Source: Arkham “A tagged SpaceX address just moved Bitcoin for the first time in 6 months. SpaceX (15atF) made a test transaction of $88 of BTC to SpaceX (bc1q9). Is SpaceX about to move more BTC?” Arkham posed.

Follow us on X to get the latest news as it happens

The question posed by Arkham itself fuels speculation. Tiny test sends are a standard custody step that verifies a new address before larger sums follow.

SpaceX has followed this playbook before. In October 2025, Arkham research recorded 2,495 BTC, worth $257 million, landing in two fresh wallets after months of quiet. That followed a $300 million shift to Coinbase Prime custody in July 2025.

SPACEX MOVING $250 MILLION BTC

SpaceX has just moved a total of $268.5 Million BTC. This involves them moving 90 and 10 BTC to separate wallets, with the other $257.7M remaining in SpaceX wallets.

What is SpaceX doing with 100 BTC? pic.twitter.com/Hb4rPBx7Ma

— Arkham (@arkham) October 21, 2025 Traders also remember that SpaceX has sold before. Arkham’s records show it offloaded two large chunks of its stack during the 2022 crypto winter. Tesla, by contrast, has left its 11,509 BTC untouched since 2024.

No Evidence of a Sale as Holdings Stay at 18,712 BTCStill, nothing currently points to selling. BitcoinTreasuries shows 18,712 BTC, unchanged since the May 21 S-1 filing that preceded SpaceX’s June 12 IPO.

SpaceX BTC Holdings. Source: Bitcoin TreasuriesThat filing also reframed what wallet watchers can see. On-chain trackers had estimated roughly 8,285 BTC, so the disclosure revealed 10,427 BTC they had never traced. In other words, Arkham’s tagged addresses cover less than half the treasury.

Ownership concentrates the decision further. Musk was expected to keep a controlling stake above 85%, leaving any accumulation or disposal at his discretion.

The timing adds intrigue. SpaceX stock joined the Nasdaq-100 this week, while BTC trades near $62,060, roughly half its October peak of $126,080. Consequently, the stash is worth about $1.2 billion, down from $1.45 billion at the time of disclosure.

Wallet data can move sentiment fast. Reports of MicroStrategy’s larger-than-reported sales showed as much just last week. Similarly, activity from long-dormant Bitcoin wallets tends to signal consolidation rather than selling.

If precedent holds, the $88 send points to custody housekeeping rather than an exit. However, follow-up transfers from the new address in the coming days would reveal whether a larger reshuffle is underway.

Germany’s seized Bitcoin wallet has been one of the market’s most obvious supply stories. Now the discussion is starting to change from how much BTC might still be sold to how close the selling pressure may be to ending.

The useful way to read this is not as a guaranteed price signal, but as a fresh piece of information in a market that is trying to sort real developments from noise. That does not mean Bitcoin is suddenly free of sell-side risk. Mt. Gox repayments, miners, ETFs, and macro flows all still matter. But a shrinking government wallet can change sentiment because it turns an open-ended fear into something with a visible endpoint.

For more details, visit the official Arkham platform.

TL;DR Arkham-tracked Germany-linked wallets now hold less than 20% of the seized BTC balance.The market has treated the transfers as a major source of sell pressure.If the balance keeps shrinking, traders may soon start pricing the end of that specific overhang. From pressure to exhaustion The significance of a wallet falling below 20% of its original seized balance is simple: the worst of that specific supply event may be closer to passing. Traders have spent days watching exchange transfers and assuming those coins could hit the market.

That does not mean Bitcoin is suddenly free of sell-side risk. Mt. Gox repayments, miners, ETFs, and macro flows all still matter. But a shrinking government wallet can change sentiment because it turns an open-ended fear into something with a visible endpoint.

The Market Read Do not overstate certainty; frame it as a visible supply overhang nearing exhaustion.

That is the balance readers need to keep in mind. Crypto markets are quick to turn every update into a single-direction trade, but most durable stories are more layered than that. They matter because they change positioning, incentives, infrastructure, or regulation over time.

What Comes Into Focus Now From here, the important thing is follow-through. If the source data, company update, filing, or on-chain record continues to move in the same direction, this can become part of a larger trend. If it stalls, it is still useful as a snapshot of where attention is sitting today.

For traders and readers, the cleaner takeaway is to separate the confirmed development from the speculation around it. The confirmed part is what deserves coverage. The speculation is what needs caution.

For Bitcoin readers specifically, the story is useful because it gives a clearer frame for the next few sessions. It tells them what to watch, which part of the market is reacting, and where the first obvious risk sits. That is more valuable than simply saying a token, company, or regulator has made a move. The useful work is in connecting the update to liquidity, positioning, adoption, enforcement, or user behaviour without pretending that any single headline controls the whole market.

The practical question now is whether this remains an isolated update or becomes part of a chain of follow-through. A second filing, another wallet move, fresh dashboard data, a new governance vote, or a stronger market reaction can all turn a clean single-day story into a broader narrative. Without that follow-through, it still matters, but more as a marker of where attention was concentrated on July 8 than as a complete trend on its own.

That distinction is especially important in a market where headlines can travel faster than context. A source-backed update gives readers something firmer to work with, but it does not remove liquidity risk, execution risk, or the chance that traders fade the initial reaction once the first wave of attention passes.

In that sense, the headline is only the starting point. The better read is to watch how builders, exchanges, funds, wallets, regulators, or large holders respond after the first announcement has moved through the feed.

This report is based on information from platform.arkhamintelligence.com.

This article was written by the News Desk and edited by Samuel Rae.

A Bitcoin wallet associated with SpaceX executed its first transaction in roughly six months, according to data from Arkham Intelligence. The wallet labeled as “SpaceX 15atF” transferred approximately $88 worth of BTC to another wallet, which also carries a SpaceX label and starts with “bc1q9”. This movement, though modest in value, has drawn significant attention within the cryptocurrency community due to SpaceX’s profile and the long period of inactivity.

Wallet transfer not seen as a sell signalWhile the transaction amount is small, movements involving wallets tied to major companies like SpaceX are closely watched by market participants. On-chain data analysts suggest that such minor transfers are typically interpreted as address verification, custody infrastructure testing, or internal routing exercises, rather than signals of an imminent market sale.

Arkham Intelligence announced that a wallet labeled as SpaceX moved Bitcoin for the first time in six months, sending about $88 worth of BTC to another wallet also appearing to be connected to SpaceX.

Available data does not indicate that the recent activity is related to preparation for a sale. Given that both the sender and recipient wallets bear SpaceX labels, it is most likely an internal adjustment or operational check rather than a step towards liquidating assets.

Glossary: Arkham Intelligence is an on-chain data platform analyzing blockchain transactions and labeling possible links between wallets and institutions. Although these labels are closely tracked by the market, they do not serve as official company statements.

SpaceX’s Bitcoin holdings draw attentionMarket monitoring platforms have estimated that SpaceX currently holds approximately 18,712 BTC. At current prices, that equates to a total portfolio value of about $1.16 billion. The sum transferred in this latest transaction represents only a fraction of the company’s reported Bitcoin holdings.

ItemDataAmount sentApproximately $88Dormancy periodAbout 6 monthsTotal BTC holdings18,712 BTCEstimated total value$1.16 billionThe fact that the recipient wallet is also tagged as belonging to SpaceX further reinforces the view that funds were likely moved between company-controlled addresses. Large corporations often transfer assets between internal wallets for purposes such as security audits, access verification, or operational updates.

Timing heightens market interestThe timing of this small transfer has also garnered attention. Reports that SpaceX has recently completed its initial public offering and joined the Nasdaq 100 index, which tracks major non-financial companies, have increased the public visibility of the company in capital markets.

The current blockchain record shows movement between labeled wallets, but this information alone does not demonstrate that a sale has occurred.

At present, the incident highlights only a resumption of activity in a previously dormant Bitcoin address connected to SpaceX. Whether it signifies a broader transfer or a new treasury management strategy remains unclear and will be revealed by future on-chain movements.

Disclaimer: The information contained in this article does not constitute investment advice. Investors should be aware that cryptocurrencies carry high volatility and therefore risk, and should conduct their own research.

Pay for the premium tier of any centralized AI platform, and rate limits still hit during peak hours. That’s not a bug. It’s the ceiling every centralized AI platform eventually reaches, because one company’s data centers can only handle so much demand at once, no matter how much money gets thrown at the problem.

Arbitrum, Internet Computer, and Kaspa each tackle a different piece of crypto’s scaling puzzle, yet none were built specifically to solve AI’s compute bottleneck. For anyone tracking the next 100x crypto, that’s the gap Stargate LLM’s Grid is aimed at.

What Happens When One Company’s Servers Aren’t Enough Table of Contents

What Happens When One Company’s Servers Aren’t EnoughLG’s Enterprise Bet on Arbitrum Hasn’t Reached the Price YetA Trillion-Dollar Ambition, a $1.2 Billion RealityKaspa Rallied on Real News. Its Own Miners Sold Into the Move.Final Say The problem isn’t unique to any one AI platform. Rate limits during peak hours are the ceiling every centralized system eventually hits, because a single company’s data centers can only absorb so much demand regardless of the price tag attached to the premium tier. Stargate LLM‘s Grid takes a different structural approach: crowdsourcing compute from a distributed network of contributors instead of concentrating it inside one company’s server farms, so capacity grows as more people join rather than staying fixed to one balance sheet.

This is the pitch for power users and businesses who’ve personally hit a rate limit or a slowdown on a paid tier, an experience that’s rarely discussed publicly but genuinely frustrating: paying full price for capacity that isn’t reliably there the moment demand spikes. Stargate LLM’s chat, image generation, video generation, private search, and agent marketplace all sit on top of that distributed compute layer rather than a single data center somewhere.

The presale runs across ten pricing stages, from $0.0005 to $0.0125, on the way to a confirmed $0.025 launch price. Stage 1 carries a 50x ratio to that target, the widest gap in the entire structure. Total supply is fixed at 150 billion tokens. Of that, 96% goes to community, ecosystem, and presale participants, and just 1% sits with the core team.

For anyone genuinely hunting the next 100x crypto, a decentralized compute layer paired with a presale still priced before the wider market has weighed in is a different kind of bet than a token riding purely on speculation.

LG’s Enterprise Bet on Arbitrum Hasn’t Reached the Price Yet LG Electronics partnered with Arbitrum to build a custom Layer 2 blockchain for automating digital advertising transactions, completing a pilot with a Japanese advertising agency and evaluating a commercial rollout before the end of 2026.LG Electronics partnered with Arbitrum to develop a custom Layer 2 blockchain designed to automate the buying and selling of digital advertising, completing a pilot with a Japanese advertising agency.

That’s a real enterprise validation of Layer 2 technology. ARB trades near $0.08, roughly 97% below its all-time high of $2.40 set in January 2024, and a scheduled token unlock on July 16 will release close to 93 million ARB, adding fresh supply pressure right as the enterprise story is still building momentum.

A Trillion-Dollar Ambition, a $1.2 Billion Reality Internet Computer positions itself as sovereign, decentralized cloud infrastructure capable of hosting entire applications on-chain, aimed squarely at the trillion-dollar cloud computing market currently dominated by centralized providers.

The Internet Computer is a decentralized cloud blockchain that pursues the $1+ trillion cloud market, hosting apps, websites, and enterprise systems fully onchain. The ambition is genuinely large. The market cap isn’t. ICP trades near $2.14 to $2.18, with a total valuation just over $1.2 billion, sitting roughly 99.7% below its all-time high near $700.

Kaspa Rallied on Real News. Its Own Miners Sold Into the Move. Kaspa is trading near $0.030, with a market cap around $830 million, after a recent smart contract hard fork and network upgrade triggered a short-term price surge. As of Jul 7, 2026, Kaspa (KAS) is trading at $0.0302 with a market cap of $830.20M, having recently experienced short-term volatility due to a network upgrade and smart contract hard fork.

That surge has since run into resistance, and heavy miner distribution is adding sell pressure right as the technical setup tries to hold its gains.

Final Say A real enterprise partnership, a trillion-dollar ambition, and a genuine network upgrade, Arbitrum, Internet Computer, and Kaspa each have something legitimate behind this week’s price action, even if none of it has fully shown up in the charts yet.

None of the three was purpose-built to solve AI’s specific compute ceiling, which is exactly what Stargate LLM’s decentralized Grid is aimed at. Stage 1 remains open before the price steps up through nine more stages.

Four different bets on the same underlying question: whose infrastructure is actually built to scale with what comes next.

Disclaimer: This is a Press Release provided by a third party who is responsible for the content. Please conduct your own research before taking any action based on the content.

On-chain sleuth ZachXBT reported that LAB has plunged 85% over the past 24 hours, dropping from $14 to just under $2. At the $14 price level, its fully diluted valuation (FDV) reached $14 billion. Disappointingly, Binance, Bitget, and Gate failed to take action earlier to prevent this incident. He stated that if centralized exchanges (CEXs) truly prioritize their users, they should at minimum distribute profits generated by price-manipulating accounts to users. ZachXBT also added that LAB investor unlocks were originally scheduled to begin later this month, but multiple late-stage vesting period adjustments have occurred previously. He alleged that insiders control the entire circulating supply and have executed extreme price manipulation on CEXs through market makers. Trading LAB is not encouraged under any circumstances.

Relevant content

Ondo Perps' trading volume has surpassed $2 billion within 48 hours of its launch.

According to official sources, Ondo announced that the cumulative trading volume of its Ondo Perps public beta exceeded $2 billion within the first 48 hours after its launch.

3 hours ago

Michael Saylor: Concerns over Bitcoin block space shortage are gradually easing, while global transfers still maintain low fees.

MicroStrategy founder Michael Saylor published an article noting that after a decade of concerns over insufficient block space and controversies surrounding non-monetary use cases, Bitcoin still has no so-called "spam transaction problem." Currently, Bitcoin network fees stand at approximately 1 sat/vB, enabling anyone to quickly transfer any amount of Bitcoin globally for roughly $0.3. Free market mechanisms have been consistently resolving the challenges facing Bitcoin's block space.

3 hours ago

Sources: Iran will close the Strait of Hormuz if the US launches an attack.

According to CCTV News, sources from Iran’s security department stated that if the U.S. launches any attack on Iran, Iran will close the Strait of Hormuz and retaliate against enemy targets with a response at least twice the scale of the strike it receives. U.S. President Donald Trump said on the 8th while attending the NATO summit in Turkey that he is very unhappy with Iran, the U.S. military “could strike Iran hard again tonight” and may also reimpose a naval blockade on Iran.

3 hours ago

BNP Paribas: Merger between Tesla and SpaceX is far from imminent

BNP Paribas analysts have expressed doubt over the recent possibility of a merger between Tesla and SpaceX. "The massive cash burn and significant regulatory risks of both companies complicate a potential merger between SpaceX and Tesla," they stated. The investor sentiment for Tesla, which has improved amid merger speculation, may be overly optimistic, and the analysts maintained their "underperform" rating and $280 target price for the firm. "We are concerned that Tesla will face daunting KPIs in its robotaxi and Optimus businesses over the next two years, which will pose downside risks to its core operations before any SpaceX merger is actually realized."

3 hours ago

Trump: Will See If He Can Continue Keeping Oil Prices Low, Notes That Oil Prices Should Remain Low

US President Trump said, "We will see if we can continue to push oil prices lower. We should maintain low oil prices."

3 hours ago

A whale has aggregated approximately $5.85 million worth of HYPE and LIT assets into the same wallet.

According to monitoring by Onchain Lens, a crypto whale has transferred approximately $5.85 million worth of HYPE and LIT assets into a single wallet, with the funds likely accumulated through Galaxy Digital. The transferred assets consist of 78,100 HYPE tokens (valued at around $5.25 million) and 263,700 LIT tokens (worth approximately $601,000).

3 hours ago

In response to the widely spread online "Gate stolen 1.7 million" incident, platform founder and CEO Dr. Han tweeted: "All the details of the incident are here. Some controversies will become clear after reading." Earlier, Gate’s official account had already released a full disclosure and review of the event. Earlier today, Gate issued an official announcement concluding that the viral "Gate stolen 1.7 million" news is not a systemic risk or website security issue, and currently guarantees the safety of all users’ assets and accounts. The incident has multiple suspicious points. The user previously completed facial live verification, provided three specified historical transaction records from 2019 as proof, and reset security settings via the original email verification code. All reset procedures were verified correctly through email code and fund password. Before processing the user’s five withdrawal requests, Gate conducted comprehensive identity verification including facial live verification, Google verification code, and fund password verification, all of which passed, before approving the withdrawals. The user subsequently reported the theft to Gate’s customer service. Gate confirms the above information is authentic and valid; all disclosed content is sourced from the platform’s complete backend operation data.

Relevant content

Ondo Perps' trading volume has surpassed $2 billion within 48 hours of its launch.

According to official sources, Ondo announced that the cumulative trading volume of its Ondo Perps public beta exceeded $2 billion within the first 48 hours after its launch.

3 hours ago

Michael Saylor: Concerns over Bitcoin block space shortage are gradually easing, while global transfers still maintain low fees.

MicroStrategy founder Michael Saylor published an article noting that after a decade of concerns over insufficient block space and controversies surrounding non-monetary use cases, Bitcoin still has no so-called "spam transaction problem." Currently, Bitcoin network fees stand at approximately 1 sat/vB, enabling anyone to quickly transfer any amount of Bitcoin globally for roughly $0.3. Free market mechanisms have been consistently resolving the challenges facing Bitcoin's block space.

3 hours ago

Sources: Iran will close the Strait of Hormuz if the US launches an attack.

According to CCTV News, sources from Iran’s security department stated that if the U.S. launches any attack on Iran, Iran will close the Strait of Hormuz and retaliate against enemy targets with a response at least twice the scale of the strike it receives. U.S. President Donald Trump said on the 8th while attending the NATO summit in Turkey that he is very unhappy with Iran, the U.S. military “could strike Iran hard again tonight” and may also reimpose a naval blockade on Iran.

3 hours ago

BNP Paribas: Merger between Tesla and SpaceX is far from imminent

BNP Paribas analysts have expressed doubt over the recent possibility of a merger between Tesla and SpaceX. "The massive cash burn and significant regulatory risks of both companies complicate a potential merger between SpaceX and Tesla," they stated. The investor sentiment for Tesla, which has improved amid merger speculation, may be overly optimistic, and the analysts maintained their "underperform" rating and $280 target price for the firm. "We are concerned that Tesla will face daunting KPIs in its robotaxi and Optimus businesses over the next two years, which will pose downside risks to its core operations before any SpaceX merger is actually realized."

3 hours ago

Trump: Will See If He Can Continue Keeping Oil Prices Low, Notes That Oil Prices Should Remain Low

US President Trump said, "We will see if we can continue to push oil prices lower. We should maintain low oil prices."

3 hours ago

A whale has aggregated approximately $5.85 million worth of HYPE and LIT assets into the same wallet.

According to monitoring by Onchain Lens, a crypto whale has transferred approximately $5.85 million worth of HYPE and LIT assets into a single wallet, with the funds likely accumulated through Galaxy Digital. The transferred assets consist of 78,100 HYPE tokens (valued at around $5.25 million) and 263,700 LIT tokens (worth approximately $601,000).

3 hours ago